Pharmacokinetic and pharmacodynamic principles in the treatment of children with otitis media
DOI:
https://doi.org/10.51481/amc.v48i3.460Keywords:
pharmacokinetic, pharmacodynamic, otitis mediaAbstract
Because acute respiratory infections and particularlyacute otitis media (AOM), are the most common cause ofantimicrobial prescription in pediatric patients, it is important to optimize antimicrobial therapies. It is essential thatbefore prescribing an antimicrobial agent, the AOM diagno-sis is well established and the local microbiological patternis known. The present review incorporates novel conceptsfor the selection of the antimicrobial therapy in childrenwith AOM taking into account pharmacokinetic and phar-macodynamic principles applied to microbiologycal concepts. These new concepts have revolutionized the treatment of diverse infectious diseases in pediatric patients andparticularly in the treatment of children with otitis media. Figura 3. Relación farmacológica para la azitromicina.Niñoscon infecciones causadas por S. pneumoniaesusceptibles amacrólidos responden bien a la azitromicina, pues este patógenotiene una MIC de 0.06 μg/mLy la azitromicina tiene unabuena cobertura sobre él mismo, no así para patógenos como H.influenzaeo S. pneumoniaeresistente a macrólidos, con unas MICque sobrepasan la cobertura del antibiótico 25-27.Tratamiento de niños con otitis media.
Downloads
References
Álvarez L. Otitis media aguda: nuevo enfoque terapéutico. RevCubana Pediatr 2004; 76:0-0
López FJ. Epidemiología de las infecciones respiratorias agudas enniños: panorama regional. En: Benguigui Y. Infecciones respirato-rias en niños. Washington, DC, 1997: 3-20.
Faden H, DuffyL, Boeve M. Otitis media: back to basics. PediatricInf Dis J 1998; 17: 1105-12.
Arguedas A, Dagan R, Soley C, Loaiza C, Knudsen K, Porat N, et al.Microbiology of otitis media in Costa Rican children, 1999 through2001. Pediatr Infect Dis J 2003; 22: 1063-8
Sierra H, Schultz M, Loaiza C, Arguedas A. Otitis media: conceptosactuales. Acta med. Costarric 2004; 46: 125-131.
Labarca J. Nuevos conceptos en farmacodinamia: ¿Debemos repen-sar como administrar antimicrobianos?. Rev. Chil. Infectol. 2002;19: 33-37.
Barberán, J. Farmacodinamia como predictor de eficacia: la visióndel clínico. Rev Esp Quimioterap. 2005; 18: 63-64
Guevara S, Soley C, Arguedas A. Seasonal patterns of otitis mediapathogens distribution in Costa Rica Children during period 1999-2004.
Dagan R, Leivovitz E. Bacterial eradication in the treatment of otitismedia. The Lancet Infection Diseases. 2002;2: 593-604
Soley C, Arguedas A. Sigle-dose azithromycin for the treatment ofchildren with acute otitis media. Expert Rev. Anti Infect. Ther. 2005;3: 707-717
American Academy of Pediatrics, American Academy of FamilyPhysicians, subcommittee on management of acute otitis media.Diagnosis and management of acute otitis media. Pediatrics. 2004;113: 1451-1465
García E. Farmacocinéticas/Farmacodinamia y el desarrollo denuevas formulaciones en el campo de los antimicrobianos. Rev EspQuimioterap. 2005; 18: 65-69
Soriano F. Farmacodinamia: factor predictivo de eficacia. AnalesEspañoles de Pediatría. 2002; 56: 25-30
Sevillano D, Jiménez M.J, Aguilar L, Prieto J. ¿Es la farmacocinéti-ca una herramienta útil para la prevención de las resistencias? RevEsp Quimioterap. 2005 18: 77-79
Zhao X, Drlica K, Restricting the selection of antibiotic-resistantmutant bacteria: Measurement and potential use of the mutant selec-tion window. J Infect Dis. 2002; 185: 561-565.
Smith H.J, Nichol K.A, Hoban D.J, Zhanel G.G. Stretching the mutantprevention concentration (MPC) beyond its limits. J AntimicrobChemother 2003; 51:1323-1325
Zhao X. Clarification of MPC and the mutant selection window con-cept. J. Antimicrob Chemother 2003; 52: 731
Hovde L, Rotchasfer E, Ibrahim H, Gunderson B, Hermsen D,Rotchafer C. Mutation prevention concentration of ceftriaxona,meropenen, imipenen, and ertapenen against three strains ofStreptococcus pneumoniae . Diagn Microbiol Infect Dis 2003; 45:265-567.
Howie VM. Otitis media. Pediatr Rev 1993; 14: 320-23
Dagan R, Abramson O, Leibovitz E, Greenberg D, Lang R, GoshenS, et al. Bacteriologic response to oral cephalosporins: Are estab-lished susceptibility breakpoints appropriate in the case of acute oti-tis media? J Infect Dis 1997; 176:1253-59
Dagan R, Leibovitz E, Fliss DM, Leiberman A, Jacobs MR, Craig W,et al. Bacteriologic efficacy of oral azithromycin and oral cefaclor intreatment of acute otitis media in infants and young children.Antimicrob Agents Chemother 2000; 44: 43-50.
Fung-Tomc J, Kolek B, Bonner DP. Ciprofloxacin - induced, lowlevel resistance to structurally unrelated antibiotic in Pseudomonasaeruginosa and methicillin- resistant Staphylococcus aureus.Antimicrob Agents Chemother 1993; 37: 1289-1296.
Coyle EA, Rybak MA. Evaluation of the activity of the newer fluo-roquinolonas against ciprofloxacin - resistant Streptococcus pneumo-niae. (Abstract 18, p 5). In: 39th Interscience Conference onAntimicrobial Agents and Chemotherapy, San Francisco, CA, 1999
Lacy MK, Lu W, Xu X, Tessier PR, Nicolau DP, Quintilliana R el al.Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, andampicillin against Streptococcus pneumoniae in an in-vitro model ofinfection. Antimicrob Agents Chemother 1999; 43: 672-677
Jacobs R. Optimisation of antimicrobial therapy using pharmacoki-netic and pharmacodynamic parameters. Clin Microbiol Infect 2001;7: 589-596.
Dagan R, Leibovitz E, Leiberman A, Yagupsky D. Clinical signifi-cance of antibiotic resistance in acute otitis media and implication ofantibiotic treatment on carriage and spread of resistance organisms.Pediatr Infect Dis J 2000; 19:S57-65.
Dagan R, Johnson CE, McLinn S et al. Bacteriologic and clinical effi-cacy of amoxicillin / clavulanate vs. azithromycin in acute otitismedia. Pediatr Infect Dis J 2000; 19: 95 - 104.
Dagan R, Leibovitz E, Greenbert D, Yagupsky P, Fliss D, LeibermanA. Early eradication of pathogens from middle ear fluid duringantibiotic treatment of acute otitis media is associated with improvedclinical outcome. Pediatr Infect Dis J 1998; 17: 776-782.
Asher E, Greenberg D, Dagan R, Porat N, Leibovitz E. Failure toeradicate otitis media pathogens after 3-5 days of treatment is associ-ated with higher relapse rate in children with initial improvement /cure. (Abstract G-2096, p. 271). In: Program and Abstracts of the44th Interscience Conference on Antimicrobial Agents andChemotherapy, October 30-November 2, 2004, Washington, DC.
Dagan R, McCracken GH. Flaws in design and conduct of clinicaltrial in acute otitis media. Pediatr Infect Dis J 2002:21:894-902.
Dagan R, Leibovitz E, Arguedas A, Hoberman A, Pichichero M,Buscan T, Paris M, Bucofzer S. The Clinical and bacteriological effi-cacy of a once daily (OD) increased dose (ID) (25mg/kg) of cefdinir(CEF) in children with acute otitis media (AOM) at high risk of per-sistent/recurrent otitis media (HR-PROM). (Abstract 1121, p 259).In: 44th Interscience Conference on Antimicrobial Agents andChemotherapy, Washington, D C, October 2004.
Downloads
Published
Issue
Section
License
Copyright (c) 2008 Acta Médica Costarricense
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Los autores que publican en la revista Acta Médica Costarricense pueden distribuir, copiar, remezclar, retocar, leer, descargar, imprimir, buscar y crear a partir de su obra de modo no comercial, indicando los créditos a la revista y sus autores y compartir su obra en las mismas condiciones. Para ello se aplica la licencia Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional(CC BY-NC-SA 4.0)
